EUVIMEDEUVIMED entdecken
Crossref

Incidence and factors associated with PrEP discontinuation in France

Nina Garofoli iD, Martin Siguier iD, Olivier Robineau iD, Michel Valette, Bao Phung, Antoine Bachelard, Christophe Rioux, Sylvie Le Gac, Marc Digumber, Gilles Pialoux, Jade Ghosn iD, Karen Champenois

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Nina Garofoli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique-Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

HIV pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but some seroconversions occur due to poor adherence or PrEP discontinuation. Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations.

Methods

A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022. PrEP users who attended at least twice within 6 months during study period were included and followed up until December 2022. The incidence rate of PrEP discontinuation was estimated by censoring lost to follow up individuals. Factors associated with PrEP discontinuations were identified using a multivariate Cox model.

Results

A total of 2785 PrEP users were included, with 94% men and 5% transgender people. Median age was 35 years. By December 2022, 653 users had stopped PrEP (24%). The incidence rate was 10.8 PrEP discontinuations for 100 person-years (PY). The main causes of discontinuation were being in a stable relationship (32%), and not judging the treatment useful anymore (12%). Individuals who discontinued PrEP were younger [<29, HR = 1.45 (1.17–1.80)], and more likely to be women [HR = 2.44 (1.50–3.96)] or sex workers [HR = 1.53 (0.96–2.44)]. They were more likely to report PrEP side effects [HR = 2.25 (1.83–2.77)] or ≥2 sexually transmitted infections [HR = 1.87 (1.53–2.27)] during the last year.

Conclusion

The incidence of PrEP discontinuations was quite low compared to rates observed in other cohorts. Users who stopped PrEP were sometimes still exposed to HIV, emphasizing the need for targeted interventions to prepare and support PrEP discontinuations and limit seroconversion risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsHumansFranceFemaleMaleAdultRetrospective StudiesIncidenceMiddle AgedYoung AdultDrug Monitoring

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases and Sexual Health Clinic, Assistance Publique-Hopitaux de Paris Nord, Bichat-Claude Bernard Hospital, Paris, France.
  • Department of Infectious Diseases, Assistance Publique-Hopitaux de Paris, Tenon Hospital, Paris, France.
  • Department of Infectious Diseases, Université Sorbonne Paris Nord, Paris, France.
  • Hospital Center of Tourcoing, Universitary Service of Infectious Diseases and Travel Medicine, Tourcoing, France.
  • Department of Research (Coordinator), COREVIH Ile-de-France Nord, Paris, France.
  • Inserm UMR1137, Université Paris Cité and Université Sorbonne Paris Nord, IAME, Paris, F-75018, France.

ORCID-Profile: Nina Garofoli, Martin Siguier, Olivier Robineau, Jade Ghosn

Zitieren

APA

Garofoli, N., Siguier, M., Robineau, O., Valette, M., Phung, B., Bachelard, A., Rioux, C., Le Gac, S., Digumber, M., Pialoux, G., Ghosn, J., & Champenois, K. (2024). Incidence and factors associated with PrEP discontinuation in France. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae133

Vancouver

Garofoli N, Siguier M, Robineau O, Valette M, Phung B, Bachelard A, et al. Incidence and factors associated with PrEP discontinuation in France. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae133

BibTeX
@article{Garofoli2024,
  author = {Garofoli, Nina and Siguier, Martin and Robineau, Olivier and Valette, Michel and Phung, Bao and Bachelard, Antoine and Rioux, Christophe and Le Gac, Sylvie and Digumber, Marc and Pialoux, Gilles and Ghosn, Jade and Champenois, Karen},
  title = {Incidence and factors associated with PrEP discontinuation in France},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae133}
}
Kostenlos starten →